Evolent Health (NYSE:EVH) has received mixed analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, and 1 indifferent rating. Over the past 3 months, 4 analysts have set a 12-month price target for EVH, averaging $39.75, which is a slight decrease from the previous target of $40.00. The high target is $46.00 and the low is $34.00. Analysts' ratings are based on financial predictions and company performance assessments.